Prevention of Congenital Toxoplasmosis With Pyrimethamine + Sulfadiazine Versus Spiramycine During Pregnancy
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Background : When a mother contracts toxoplasmosis during pregnancy, the parasite may be
transmitted from to her unborn child. This results in congenital toxoplasmosis, which may
cause damage to the eyes and nervous system of the child. To date, no method has been proved
effective to prevent this transmission. In France, spiramycin is usually prescribed to women
who have toxoplasma seroconversion in pregnancy, however its efficacy has not been
determined. The standard treatment for toxoplasmosis is the combination of the antiparasitic
drugs pyrimethamine and sulfadiazine, but this strategy has not been evaluated for the
prevention of mother-to-child transmission.
Purpose : Randomized phase 3 trial to determine whether pyrimethamine + sulfadiazine is more
effective than spiramycin to prevent congenital toxoplasmosis.